White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Gold Prices Retreat From Two-Month High as Softer Inflation Eases Fed Rate Hike Bets 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
UK Economy Posts Surprise June Growth as World Cup and Hot Weather Lift Activity 
US Dollar Slips as Softer PPI Data Eases Fed Rate Hike Expectations 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Canada-US Trade Talks Gain Momentum Ahead of Aug. 19 Tariff Deadline 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
KOSPI Eyes Best Weekly Gain Since June as Samsung, SK Hynix Rally 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Add as a preferred source on Google
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
